Former AusCann chief executive Layton Mills has joined the board of MGC Pharma as a non-executive director.
Mills is the founder of CanPal Animal Therapeutics which he sold to AusCann in November 2020 for A$17.5 million. He became group CEO the following year.
But amid a difficult financial environment CanPal was effectively mothballed, with AusCann eventually selling 52% of the business back to Mills earlier this year. He had already left his CEO role and was among the contestants looking for love on TV reality show Married at First Sight earlier this year.
Mills is also the founder and managing director of Subgenix Lifesciences, which is described as an early-stage biotech looking to use psychedelic compounds to treat rare and underserved health needs.
MGC said Mills will bring his “significant experience across human and animal health in pharmaceutical and consumer healthcare”.
The company last week said it was making changes to its board and UK advisers in a move away from medicinal cannabis to a more pharmaceutical-focused strategy.
